Fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin

In this post hoc analysis we investigated the effects of insulin degludec/liraglutide fixed‐ratio combination (IDegLira) versus comparators on cardiovascular (CV) risk markers in participants in the DUAL II (vs. insulin degludec), DUAL V (vs. insulin glargine 100 units/mL) and DUAL VII (vs. basal–bo...

Descripción completa

Detalles Bibliográficos
Autores principales: Vilsbøll, Tina, Blevins, Thomas C., Jodar, Esteban, Poulter, Neil, Tentolouris, Nikolaos, Ross Agner, Bue F., Lehmann, Lucine, Leiter, Lawrence A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593827/
https://www.ncbi.nlm.nih.gov/pubmed/30785655
http://dx.doi.org/10.1111/dom.13675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593827/
https://www.ncbi.nlm.nih.gov/pubmed/30785655
http://dx.doi.org/10.1111/dom.13675

Ejemplares similares